Intelligent Bio Solutions Achieves Record Monthly Sales of 12,500+ Units of Higher-Margin Cartridges in July
Intelligent Bio Solutions (Nasdaq: INBS) reported record-breaking monthly cartridge sales in July 2025, shipping 519 boxes containing over 12,500 cartridges, marking a 60% year-over-year increase. The company's fingerprint sweat-based drug testing system operates on a razor/razor blade business model, where cartridges serve as high-margin consumables.
INBS secured a significant multi-site contract in the transportation sector and is experiencing growing demand for its drug testing solutions. The company plans to expand beyond Forensic Use Only settings in the U.S. market during the second half of 2025, while focusing on leveraging its installed base to drive recurring cartridge sales.
Intelligent Bio Solutions (Nasdaq: INBS) ha registrato a luglio 2025 vendite mensili di cartucce da record, spedendo 519 scatole contenenti oltre 12.500 cartucce, pari a un aumento del 60% su base annua. Il sistema di test antidroga su sudore basato su impronte digitali dell'azienda segue un modello razor/razor blade, con le cartucce come consumabili ad alta marginalità.
INBS ha ottenuto un importante contratto multi-sito nel settore dei trasporti e rileva una domanda in crescita per le sue soluzioni di testing. La società prevede di estendere l'utilizzo oltre gli ambiti "Forensic Use Only" nel mercato statunitense nella seconda metà del 2025, concentrandosi nel contempo sullo sfruttamento della base installata per incrementare le vendite ricorrenti di cartucce.
Intelligent Bio Solutions (Nasdaq: INBS) registró en julio de 2025 ventas mensuales de cartuchos históricas, enviando 519 cajas con más de 12.500 cartuchos, lo que supone un 60% de incremento interanual. El sistema de detección de drogas en sudor por huella digital de la compañía funciona con un modelo razor/razor blade, en el que los cartuchos son consumibles de alto margen.
INBS consiguió un contrato multisede importante en el sector del transporte y está observando una demanda creciente de sus soluciones de pruebas. La empresa planea expandirse más allá de los entornos "Forensic Use Only" en el mercado estadounidense durante la segunda mitad de 2025, centrándose en aprovechar su base instalada para impulsar las ventas recurrentes de cartuchos.
Intelligent Bio Solutions (Nasdaq: INBS)는 2025년 7월에 카트리지 월간 판매 신기록을 세우며 519박스에 포함된 12,500개 이상 카트리지를 출하해 전년 대비 60% 증가
INBS는 운송 부문에서 다수 사이트를 포함한 주요 계약을 확보했으며, 자사의 약물 검사 솔루션에 대한 수요가 증가하고 있습니다. 회사는 2025년 하반기 미국 시장에서 'Forensic Use Only' 범위를 넘어 확장을 계획하고 있으며, 설치 기반을 활용해 카트리지의 반복 판매를 확대하는 데 주력할 예정입니다.
Intelligent Bio Solutions (Nasdaq: INBS) a enregistré en juillet 2025 des ventes mensuelles de cartouches record, expédiant 519 boîtes contenant plus de 12 500 cartouches, soit une hausse de 60% sur un an. Le système de dépistage de drogues dans la sueur basé sur les empreintes digitales fonctionne selon un modèle razor/razor blade, où les cartouches constituent des consommables à forte marge.
INBS a obtenu un contrat multi-site important dans le secteur des transports et constate une demande croissante pour ses solutions de dépistage. La société prévoit de s'étendre au-delà des environnements "Forensic Use Only" sur le marché américain durant la seconde moitié de 2025, tout en mettant l'accent sur l'exploitation de sa base installée pour stimuler les ventes récurrentes de cartouches.
Intelligent Bio Solutions (Nasdaq: INBS) meldete im Juli 2025 rekordverdächtige monatliche Kartuschenverkäufe und verschiffte 519 Kartons mit über 12.500 Kartuschen, was einem 60%igen Anstieg im Jahresvergleich entspricht. Das schweißbasierte Drogentest-System des Unternehmens auf Fingerabdruck-Basis folgt einem Razor/Razor-Blade-Geschäftsmodell, wobei die Kartuschen als margenstarke Verbrauchsmaterialien dienen.
INBS sicherte sich einen bedeutenden Multi-Site-Vertrag im Transportsektor und verzeichnet eine steigende Nachfrage nach seinen Testlösungen. Das Unternehmen plant, in der zweiten Jahreshälfte 2025 über "Forensic Use Only"-Einsätze im US-Markt hinauszugehen und zugleich die installierte Basis zu nutzen, um wiederkehrende Kartuschenverkäufe zu fördern.
- Record monthly sales of 12,500+ cartridges, representing 60% year-over-year growth
- Secured new multi-site, high-volume contract in transportation sector
- Higher-margin consumables driving recurring revenue stream
- Growing pipeline of significant opportunities with increasing bids and tenders
- U.S. market expansion limited to Forensic Use Only settings until second half of 2025
Insights
INBS reports record cartridge sales showing 60% YoY growth, validating their razor/razor-blade model with high-margin recurring revenue.
Intelligent Bio Solutions has achieved a significant operational milestone with record monthly cartridge sales for July 2025, shipping 519 boxes representing over 12,500 cartridges. This marks a substantial
The cartridge sales are especially important as they represent the higher-margin consumable component in INBS's fingerprint sweat-based drug testing system. This follows the classic razor/razor-blade business model where initial equipment sales lead to ongoing consumable purchases. For medical technology companies, these recurring revenue streams typically carry gross margins of
The growth driver appears two-fold: First, INBS has secured a significant multi-site contract in the transportation sector, immediately boosting cartridge demand. Second, their expanding installed base naturally creates a compounding effect on consumable usage. This virtuous cycle is fundamental to successful medtech businesses - each new system placement generates years of subsequent high-margin cartridge sales.
Looking ahead, the company's planned U.S. market expansion beyond Forensic Use Only settings in late 2025 represents a substantial growth catalyst. The U.S. workplace drug testing market exceeds
Company reports all-time-high monthly cartridge sales for July with
NEW YORK, Aug. 19, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced its highest-ever monthly cartridge sales for July 2025, with a record 519 boxes shipped, representing over 12,500 cartridges and a
Cartridges, a higher-margin consumable in the Company’s fingerprint sweat-based drug testing system, form the foundation of INBS’s razor/razor blade business model. This recurring revenue stream continues to grow as the Company secures new large contracts and further expands its global installed base. A recent significant tender win has secured a multi-site, high-volume contract in the transportation sector, and the continued expansion of the installed base has directly increased ongoing demand for consumables. The Company is seeing a growing pipeline of significant opportunities, with an increasing number of bids and tenders for large-scale deployments.
"July's record cartridge sales show the strength of our razor/razor blade business model and the momentum generated by major contract wins," said Harry Simeonidis, President and CEO at Intelligent Bio Solutions. "As we expand our installed base and win larger opportunities, we see continued growth in cartridge demand, delivering attractive margins and a reliable revenue stream."
INBS remains focused on leveraging its installed base to drive recurring consumable sales of the Company’s cartridges, while continuing to grow its footprint ahead of planned U.S. market expansion (beyond Forensic Use Only settings) in the second half of 2025.
About Intelligent Bio Solutions Inc.
Intelligent Bio Solutions Inc. (NASDAQ: INBS) is a medical technology company delivering intelligent, rapid, non-invasive testing solutions. The Company believes that its Intelligent Fingerprinting Drug Screening System will revolutionize portable testing through fingerprint sweat analysis, which has the potential for broader applications in additional fields. Designed as a hygienic and cost-effective system, the test screens for the recent use of drugs commonly found in the workplace, including opiates, cocaine, methamphetamine, and cannabis. With sample collection in seconds and results in under ten minutes, this technology would be a valuable tool for employers in safety-critical industries. The Company’s current customer segments outside the US include construction, manufacturing and engineering, transport and logistics firms, mining, drug treatment organizations, and coroners.
For more information, visit https://ibs.inc/
Forward-Looking Statements
Some of the statements in this release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, which involve risks and uncertainties. Forward-looking statements in this press release include, without limitation, Intelligent Bio Solutions Inc.’s ability to successfully develop and commercialize its drug and diagnostic tests, realize commercial benefit from its partnerships and collaborations, and secure regulatory approvals, among others. Although Intelligent Bio Solutions Inc. believes that the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward-looking statements. Intelligent Bio Solutions Inc. has attempted to identify forward-looking statements by terminology, including “believes,” “estimates,” “anticipates,” “expects,” “plans,” “projects,” “intends,” “potential,” “may,” “could,” “might,” “will,” “should,” “approximately” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are only predictions and involve known and unknown risks, uncertainties, and other factors, included in Intelligent Bio Solutions’ public filings filed with the Securities and Exchange Commission. Any forward-looking statements contained in this release speak only as of its date. Intelligent Bio Solutions undertakes no obligation to update any forward-looking statements contained in this release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events.
Company Contact
Intelligent Bio Solutions Inc.
info@ibs.inc
LinkedIn | Twitter
Investor & Media Contact
Valter Pinto, Managing Director
KCSA Strategic Communications
PH: (212) 896-1254
INBS@kcsa.com
FAQ
What were Intelligent Bio Solutions (INBS) cartridge sales in July 2025?
How does INBS's razor/razor blade business model work?
When will INBS expand beyond Forensic Use Only settings in the U.S. market?
What new contracts has INBS secured recently?
What is driving INBS's revenue growth?
